Advertisement

Topics

The Center for Biosimilars Company Profile

04:23 EST 18th January 2019 | BioPortfolio

The Center for Biosimilars® is a digital resource that serves as a platform for health economic experts, managed care professionals, key clinical specialists and other authoritative industry voices, to share information on emerging technologies, with a focus on improving critical thinking in the field to affect patient outcomes. The Center for Biosimilars®, which was cited in a United States Senate testimony on drug prices and out-of-pocket costs for rheumatoid arthritis drugs, discusses the current landscape for advanced healthcare management.


News Articles [937 Associated News Articles listed on BioPortfolio]

STAT Plus: You have questions on biosimilars. We have answers

What do patent thickets mean for biosimilars? How much cheaper are biosimilars than branded drugs? And what about "pay to delay" moves?

Biosimilars applications under review by EMA – June 2018

The European Medicines Agency (EMA) is the body responsible for approval of biosimilars within the European Union (EU). A legal framework for approving biosimilars was established in 2003. Approval of...

Biosimilars Have the Potential to Deliver Dramatic Cost Savings for US and European Healthcare Systems

LONDON–(BUSINESS WIRE)–Celltrion Healthcare outlined their vision of ‘shaping future healthcare by improving access to biosimilars’ at the 5th Annual Biosimilars USA Conference in New...

ICS Opens New 3PL Distribution Center

New flagship distribution center to serve pharma manufacturers of specialty medications, biosimilars, cell and gene therapies

Recommendations for biosimilars in rheumatology in the Middle East

The increasing availability of biosimilars in Middle Eastern regions may provide an opportunity to increase the number of rheumatology patients who have access to traditionally more expensive biologic...

How will the US market respond to Coherus’s two new biosimilars?

Biosimilars, or highly similar versions of high-price biologics, continue to grab market headlines with their sales potential. However, Coherus BioSciences’ biosimilars...Read More... The post How ...

The Good and the Bad of Biosimilars

The biosimilars market is suddenly booming, with established biopharma giants and nimble start-ups all clamoring for a piece of the action. But such steep competition means that only the wise will sur...

What does the future hold for US biosimilars?

The FDA took steps to facilitate development of biosimilars in June by withdrawing guidance issued in September 2017, titled Statistical...Read More... The post What does the future hold for US biosim...

Drugs and Medications [0 Results]

None

PubMed Articles [582 Associated PubMed Articles listed on BioPortfolio]

Biosimilars: Are They Really Safe?

An increasing availability of biosimilars is an important step in the process of delivering optimal care while improving access for patients with cancer. Evolving regulatory mechanisms deal with biosi...

Biosimilars: Expert consensus of the Latin American Society of Psoriasis (SOLAPSO) in Argentina.

With the appearance of biological treatments, therapeutics has changed in many rheumatological, dermatological and oncological diseases. Due to the high cost of these biological medicaments and the ex...

Why Biologics and Biosimilars Remain So Expensive: Despite Two Wins for Biosimilars, the Supreme Court's Recent Rulings do not Solve Fundamental Barriers to Competition.

Biologics and biosimilars are medicines made from living cells that treat common and serious diseases such as cancer, diabetes, rheumatoid arthritis, and other inflammatory diseases. They are highly t...

Biosimilars in oncology and inflammatory diseases: current and future considerations for clinicians in Latin America.

Biological therapies have revolutionized the treatment of several cancers and systemic immune-mediated inflammatory conditions. Expiry of patents protecting a number of biologics has provided the oppo...

The future landscape of biosimilars in rheumatology: Where we are where we are going.

The upcoming of biosimilars in rheumatic diseases have generated considerable interest throughout the past five years among pharmaceutical industries and regulatory agencies, their development is asso...

Clinical Trials [1753 Associated Clinical Trials listed on BioPortfolio]

Post-ASCT Use of Zarzio®

There are limited data concerning the use of biosimilars of filgrastim in autologous stem cell transplantation (ASCT). This study aimed to evaluate G-CSF efficiency and safety (based on ha...

An Explanatory Factors Analysis of Inflammatory Bowel Diseases(IBD's) Management Costs for Adults Patients Treated by Biotherapy and Followed at Nancy University Hospital

The objective of this study is to analyze the factors influencing the medical and non-medical direct costs of patients treated with biotherapy during the last twelve months (infliximab or ...

Phase II Study of Herzuma® Plus Gedatolisib in Patients With HER-2 Positive Metastatic Breast Cancer

This study is a multicenter, prospective, single-arm, phase II study to evaluate the antitumor activity and safety of trastuzumab biosimilar (herzuma®) plus gedatolisib in patients with H...

Comparative Effectiveness and Safety of Biosimilar and Legacy Drugs

In Canada and worldwide there is a need for updated independent real-world comparative effectiveness and safety data related to biologic drugs including biosimilar drugs. Biosimilar drugs ...

An Early Access Program For Ustekinumab In Participants With Moderately To Severely Active Crohn's Disease

The purpose of this program is to provide early access to ustekinumab where it is commercially unavailable for the treatment of participants with moderately to severely active Crohn's dise...

Companies [1408 Associated Companies listed on BioPortfolio]

The Center for Biosimilars

The Center for Biosimilars® is a digital resource that serves as a platform for health economic experts, managed care professionals, key clinical specialists and other a...

FINOX AG

FINOX pioneers niche Biosimilars and wants to establish itself as a respected competitor in these markets. Through our Biosimilars to come we aim to create value for patients, partners and the inve...

AAM Biosimilars Council

The Biosimilars Council, a division of the Association for Accessible Medicines (AAM), works to ensure a positive environment for patient access to biosimilar medicines. The Biosi...

Lynkogen Inc.

Alteogen Inc. is a Korea-based biopharmaceutical company that focuses on the development and commercialization of novel biologics such as Antibody-dug conjugates, biobetters and b...

Alteogen Inc.

Alteogen lnc. is a Korea-based biopharmaceutical company that focuses on the development and commercialization of novel biologics such as ADCs, biobetters and biosimilars. Alteoge...

More Information about "The Center for Biosimilars" on BioPortfolio

We have published hundreds of The Center for Biosimilars news stories on BioPortfolio along with dozens of The Center for Biosimilars Clinical Trials and PubMed Articles about The Center for Biosimilars for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of The Center for Biosimilars Companies in our database. You can also find out about relevant The Center for Biosimilars Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Biotechnology Products
BioPortfolio lists over 550 biotechnology products - please open http://www.bioportfolio.com/channels?category_id=5 Direct topic pages: Actos Advair Biopharmaceuticals Biosimilars Biotherapeutics GMO Crops Lipitor ...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...


Corporate Database Quicklinks



Searches Linking to this Company Record